Cargando…
Cardiovascular safety outcomes of once‐weekly GLP‐1 receptor agonists in people with type 2 diabetes
WHAT IS KNOWN AND OBJECTIVE: People with type 2 diabetes (T2D) are at increased risk of cardiovascular disease (CVD), which in turn is associated with increased morbidity and mortality. The impact of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) on cardiovascular (CV) outcomes has been inves...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7540076/ https://www.ncbi.nlm.nih.gov/pubmed/32910492 http://dx.doi.org/10.1111/jcpt.13226 |